Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

Advanced Material Science Meets Surgical Precision in Groundbreaking New Platform in Reconstructive Foot & Ankle Surgery Market ...

Lawmakers in both chambers have introduced legislation to require the Food and Drug Administration to study the impacts of ...

A Food and Drug Administration expert panel has reignited a debate over whether hormone therapy should be used to treat ...

More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...

Outside of hyping healthy foods, some of MAHA’s other priorities are more suspect. The 73-page MAHA report the White House ...

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

Trump celebrated when the Supreme Court limited nationwide blocks on his policies, but judges are finding other ways to hinder his priorities.

Some nutritionists said there is little benefit in substituting high-fructose corn syrup, a staple of sugary snacks and ...

More than 67,200 Power Stick deodorants have been recalled due to manufacturing violations, according to the U.S. Food and ...